| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 424237100 | Staphylococcus or Streptococcus | 8 |
| 20090068226 | Bacterial superantigen vaccines - The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described. | 03-12-2009 |
| 20090285858 | PREVENTION OF ALLERGY IN CHILDREN - The present invention relates to a use of bacterial superantigens in the manufacture of a pharmaceutical composition for mucous membrane administration for the prevention of inflammatory disorders in newborn infants, such pharmaceutical compositions, as well as method for prevention of inflammatory disorders. | 11-19-2009 |
| 20110280908 | MULTIMERIC PROTEIN TOXINS TO TARGET CELLS HAVING MULTIPLE IDENTIFYING CHARACTERISTICS - The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases. | 11-17-2011 |
| 20140010843 | METHOD OF DETOXIFICATION - The present invention relates to a method of detoxifying bacterial cytolysins such as pneumococcal pneumolysin, utilizing chemical cross-linking compounds. | 01-09-2014 |
| 20150037373 | METHOD OF ENHANCING THE PROLIFERATIVE PHASE OF A PRIMARY T CELL RESPONSE - Disclosed is an alkaline extract of shredded pinecones yields a polyphenylpropanoid polysaccharide complex (PPC) that functions as an orally active immune adjuvant. Specifically, the oral PPC boosts the number of antigen-specific memory CD8+ T cells generated in response to a variety of vaccine types (DNA, protein, and dendritic cell) and bias the response towards one that is predominately a T helper 1 type. The oral PPC has potential for use be to enhance the T cell response generated by a variety of prophylactic and therapeutic vaccines designed to target a cellular response. | 02-05-2015 |
| 20150079130 | ADJUVANT SYSTEM FOR ORAL VACCINE ADMINISTRATION - The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced T | 03-19-2015 |
| 20150079131 | Prevention of Inflammatory Disorders in Domestic Non-Human Mammals - The present invention regards use of a bacterial superantigen for administration onto the mucous membrane of a domestic non-human mammal for the prevention of inflammatory disorder, such as allergies, autoimmune and inflammatory diseases. | 03-19-2015 |
| 20160136266 | Vaccine system for vaccine adjuvant - The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced T | 05-19-2016 |
